Merck, Moderna melanoma trial hits key goals

Syringe and vaccine vial in clinic symbolizing positive melanoma trial results for MRK and MRNA

Key Points

01Phase 3 trial of Intismeran plus Keytruda met primary and key secondary endpoints
02Study involved 1,137 high-risk patients with resected stage IIB–IV melanoma
03No new safety signals emerged compared with earlier combination studies
04Merck and Moderna (MRNA) plan regulatory discussions as the trial continues

Late-stage melanoma trial delivers positive topline data

Merck and Moderna (MRNA) announced that a late-stage Phase 3 trial evaluating the personalized mRNA cancer vaccine Intismeran in combination with Keytruda achieved its main efficacy objectives in melanoma. At a pre-specified interim analysis, the combination regimen met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, outperforming Keytruda alone.

The results indicate that patients receiving Intismeran plus Keytruda experienced a longer period without their melanoma returning and a reduced risk of the cancer spreading to distant parts of the body. These findings represent a significant late-stage readout for an mRNA-based cancer vaccine approach.

Study design and patient population

The Phase 3 study enrolled 1,137 high-risk patients with stage IIB–IV melanoma whose tumors had been surgically removed. Participants were randomized to receive up to nine doses of the personalized mRNA vaccine Intismeran alongside Keytruda, or Keytruda alone, over approximately one year.

The trial specifically targeted patients at elevated risk of recurrence following surgery, assessing whether the addition of the vaccine to standard immunotherapy could improve outcomes. The ongoing study is designed to measure multiple endpoints, with recurrence-free survival and distant metastasis-free survival forming the basis of the interim analysis.

Safety profile and ongoing evaluation

Merck and Moderna (MRNA) reported that no new safety signals emerged in the Phase 3 trial. The safety profile observed for the Intismeran and Keytruda combination was consistent with earlier studies of the regimen, suggesting a similar tolerability profile as seen in prior-stage research.

While the latest data confirm benefits in recurrence-free survival and distant metastasis-free survival, the trial will continue to assess additional outcomes, including overall survival. Further follow-up will clarify the long-term impact of the combination on patient survival and disease control.

Next steps and market reaction

The companies plan to present detailed Phase 3 results at an upcoming international medical meeting. They also intend to share the data with regulatory authorities, initiating discussions on potential next steps for the regimen in the adjuvant melanoma setting.

Following the announcement of the positive topline data, shares of Moderna and Merck moved higher, reflecting investor interest in the potential of a personalized mRNA vaccine combined with an established immunotherapy. The outcome marks an important milestone in advancing mRNA technology beyond infectious disease vaccines into oncology.

Key Takeaways

01The Phase 3 success of Intismeran plus Keytruda provides late-stage evidence that a personalized mRNA vaccine can enhance outcomes in high-risk melanoma.
02Safety findings in the trial align with earlier studies, supporting the feasibility of combining personalized vaccination with standard immunotherapy.
03With regulatory engagement planned and overall survival still under evaluation, the trial’s continuation will shape the future clinical role of this regimen in melanoma care.

References